The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.
Notice of Funding Opportunities
| Title | Announcement Number | Activity Code | Clinical Trials Status | Expiration Date | Program Official Sort ascending |
|---|---|---|---|---|---|
| Basic Research in Cancer Health Disparities | PAR-21-323 (R21 Clinical Trial Not Allowed) | R21 | Clinical Trial Not Allowed | 09/08/2024 | Asad Umar, D.V.M., Ph.D. |
| Basic Research in Cancer Health Disparities | PAR-21-324 (R03 Clinical Trial Not Allowed) | R03 | Clinical Trial Not Allowed | 09/08/2024 | Asad Umar, D.V.M., Ph.D. |
| Basic Research in Cancer Health Disparities | PAR-21-322 (R01 Clinical Trial Not Allowed) | R01 | Clinical Trial Not Allowed | 09/08/2024 | Asad Umar, D.V.M., Ph.D. |
| Biology of Bladder Cancer | PAR-22-218 (R01 Clinical Trial Optional) | R01 | Clinical Trial Optional | 09/08/2025 | |
| Biology of Bladder Cancer | PAR-22-219 (R21 Clinical Trial Optional) | R21 | Clinical Trial Optional | 09/08/2025 | |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer | PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed) | UH2, UH3 | Clinical Trial Not Allowed | 10/15/2026 | Sudhir Srivastava, Ph.D., M.P.H. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer | PAR-23-314 (UH3 Clinical Trials Not Allowed) | UH3 | 10/15/2026 | Sudhir Srivastava, Ph.D., M.P.H. | |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery | PAR-21-331 (R01 Clinical Trial Optional) | R01 | Clinical Trial Optional | 09/08/2024 | Edward Sauter, M.D., Ph.D. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery | PAR-21-332 (R21 Clinical Trial Not Allowed) | R21 | Clinical Trial Not Allowed | 09/08/2024 | Edward Sauter, M.D., Ph.D. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics | PAR-23-279 (R01 Clinical Trial Optional) | R01 | Clinical Trial Optional | 01/08/2027 | Edward Sauter, M.D., Ph.D. |